Evaluating the Impact of Primary Tumor Resection on EGFR-TKI-treated Patients with Advanced Lung Cancer: A Multicenter Propensity-matched Study

Background: Nonsmall-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations is exceptionally sensitive to EGFR tyrosine kinase inhibitors (TKIs). Despite this, disease progression commonly occurs at the primary site, prompting debate on the potential advantages of incorporat...

Full description

Saved in:
Bibliographic Details
Main Authors: Eva Yu-Hsuan Chuang, Chiao-En Wu, Tzu-Wei Kuo, Yu-Wen Wen, Ping-Chih Hsu, Chih-Hsi Scott Kuo, Cheng-Ta Yang, Ling-Jen Hung, Yin-Kai Chao
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2025-04-01
Series:Journal of Cancer Research and Practice
Subjects:
Online Access:https://journals.lww.com/10.4103/ejcrp.eJCRP-D-24-00037
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1839638554689404928
author Eva Yu-Hsuan Chuang
Chiao-En Wu
Tzu-Wei Kuo
Yu-Wen Wen
Ping-Chih Hsu
Chih-Hsi Scott Kuo
Cheng-Ta Yang
Ling-Jen Hung
Yin-Kai Chao
author_facet Eva Yu-Hsuan Chuang
Chiao-En Wu
Tzu-Wei Kuo
Yu-Wen Wen
Ping-Chih Hsu
Chih-Hsi Scott Kuo
Cheng-Ta Yang
Ling-Jen Hung
Yin-Kai Chao
author_sort Eva Yu-Hsuan Chuang
collection DOAJ
description Background: Nonsmall-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations is exceptionally sensitive to EGFR tyrosine kinase inhibitors (TKIs). Despite this, disease progression commonly occurs at the primary site, prompting debate on the potential advantages of incorporating primary tumor resection alongside standard maintenance therapy. Materials and Methods: This retrospective multicenter study enrolled NSCLC patients treated with EGFR-TKIs and categorized them into surgery and control groups based on primary tumor resection. The propensity score matching (PSM) method was used to ensure balanced comparisons, accounting for 12 covariates. Progression-free survival (PFS) and overall survival (OS) were evaluated, addressing immortal time bias. Results: Among 2151 EGFR-TKI-treated patients screened from 2010 to 2019, 57 (21 surgery group, 36 control group) were included post-PSM and accounting for immortal time bias. No cases of major complications (grade IIIa or higher based on Clavien-Dindo criteria) or 90-day mortality were noted in the surgery group. Pulmonary resection was significantly associated with longer PFS (58.6 vs. 14.1 months, P = 0.001) and OS (109.6 vs. 46.6 months, P = 0.016) compared to EGFR-TKI monotherapy. Positive outcomes were consistent across diverse subgroups. Conclusion: The addition of primary tumor resection in EGFR-mutant NSCLC patients receiving EGFR-TKI treatment was associated with improved PFS and OS compared to EGFR-TKI treatment alone. However, these results should be interpreted with caution due to potential selection bias in the analysis.
format Article
id doaj-art-f73e967ef7844fcf85d2d4c4920caefe
institution Matheson Library
issn 2311-3006
language English
publishDate 2025-04-01
publisher Wolters Kluwer Medknow Publications
record_format Article
series Journal of Cancer Research and Practice
spelling doaj-art-f73e967ef7844fcf85d2d4c4920caefe2025-07-05T07:28:28ZengWolters Kluwer Medknow PublicationsJournal of Cancer Research and Practice2311-30062025-04-01122404810.4103/ejcrp.eJCRP-D-24-00037Evaluating the Impact of Primary Tumor Resection on EGFR-TKI-treated Patients with Advanced Lung Cancer: A Multicenter Propensity-matched StudyEva Yu-Hsuan ChuangChiao-En WuTzu-Wei KuoYu-Wen WenPing-Chih HsuChih-Hsi Scott KuoCheng-Ta YangLing-Jen HungYin-Kai ChaoBackground: Nonsmall-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations is exceptionally sensitive to EGFR tyrosine kinase inhibitors (TKIs). Despite this, disease progression commonly occurs at the primary site, prompting debate on the potential advantages of incorporating primary tumor resection alongside standard maintenance therapy. Materials and Methods: This retrospective multicenter study enrolled NSCLC patients treated with EGFR-TKIs and categorized them into surgery and control groups based on primary tumor resection. The propensity score matching (PSM) method was used to ensure balanced comparisons, accounting for 12 covariates. Progression-free survival (PFS) and overall survival (OS) were evaluated, addressing immortal time bias. Results: Among 2151 EGFR-TKI-treated patients screened from 2010 to 2019, 57 (21 surgery group, 36 control group) were included post-PSM and accounting for immortal time bias. No cases of major complications (grade IIIa or higher based on Clavien-Dindo criteria) or 90-day mortality were noted in the surgery group. Pulmonary resection was significantly associated with longer PFS (58.6 vs. 14.1 months, P = 0.001) and OS (109.6 vs. 46.6 months, P = 0.016) compared to EGFR-TKI monotherapy. Positive outcomes were consistent across diverse subgroups. Conclusion: The addition of primary tumor resection in EGFR-mutant NSCLC patients receiving EGFR-TKI treatment was associated with improved PFS and OS compared to EGFR-TKI treatment alone. However, these results should be interpreted with caution due to potential selection bias in the analysis.https://journals.lww.com/10.4103/ejcrp.eJCRP-D-24-00037epidermal growth factor receptorlocal consolidation therapynonsmall-cell lung cancerprimary tumor resectionprogression-free survivaltyrosine kinase inhibitors
spellingShingle Eva Yu-Hsuan Chuang
Chiao-En Wu
Tzu-Wei Kuo
Yu-Wen Wen
Ping-Chih Hsu
Chih-Hsi Scott Kuo
Cheng-Ta Yang
Ling-Jen Hung
Yin-Kai Chao
Evaluating the Impact of Primary Tumor Resection on EGFR-TKI-treated Patients with Advanced Lung Cancer: A Multicenter Propensity-matched Study
Journal of Cancer Research and Practice
epidermal growth factor receptor
local consolidation therapy
nonsmall-cell lung cancer
primary tumor resection
progression-free survival
tyrosine kinase inhibitors
title Evaluating the Impact of Primary Tumor Resection on EGFR-TKI-treated Patients with Advanced Lung Cancer: A Multicenter Propensity-matched Study
title_full Evaluating the Impact of Primary Tumor Resection on EGFR-TKI-treated Patients with Advanced Lung Cancer: A Multicenter Propensity-matched Study
title_fullStr Evaluating the Impact of Primary Tumor Resection on EGFR-TKI-treated Patients with Advanced Lung Cancer: A Multicenter Propensity-matched Study
title_full_unstemmed Evaluating the Impact of Primary Tumor Resection on EGFR-TKI-treated Patients with Advanced Lung Cancer: A Multicenter Propensity-matched Study
title_short Evaluating the Impact of Primary Tumor Resection on EGFR-TKI-treated Patients with Advanced Lung Cancer: A Multicenter Propensity-matched Study
title_sort evaluating the impact of primary tumor resection on egfr tki treated patients with advanced lung cancer a multicenter propensity matched study
topic epidermal growth factor receptor
local consolidation therapy
nonsmall-cell lung cancer
primary tumor resection
progression-free survival
tyrosine kinase inhibitors
url https://journals.lww.com/10.4103/ejcrp.eJCRP-D-24-00037
work_keys_str_mv AT evayuhsuanchuang evaluatingtheimpactofprimarytumorresectiononegfrtkitreatedpatientswithadvancedlungcanceramulticenterpropensitymatchedstudy
AT chiaoenwu evaluatingtheimpactofprimarytumorresectiononegfrtkitreatedpatientswithadvancedlungcanceramulticenterpropensitymatchedstudy
AT tzuweikuo evaluatingtheimpactofprimarytumorresectiononegfrtkitreatedpatientswithadvancedlungcanceramulticenterpropensitymatchedstudy
AT yuwenwen evaluatingtheimpactofprimarytumorresectiononegfrtkitreatedpatientswithadvancedlungcanceramulticenterpropensitymatchedstudy
AT pingchihhsu evaluatingtheimpactofprimarytumorresectiononegfrtkitreatedpatientswithadvancedlungcanceramulticenterpropensitymatchedstudy
AT chihhsiscottkuo evaluatingtheimpactofprimarytumorresectiononegfrtkitreatedpatientswithadvancedlungcanceramulticenterpropensitymatchedstudy
AT chengtayang evaluatingtheimpactofprimarytumorresectiononegfrtkitreatedpatientswithadvancedlungcanceramulticenterpropensitymatchedstudy
AT lingjenhung evaluatingtheimpactofprimarytumorresectiononegfrtkitreatedpatientswithadvancedlungcanceramulticenterpropensitymatchedstudy
AT yinkaichao evaluatingtheimpactofprimarytumorresectiononegfrtkitreatedpatientswithadvancedlungcanceramulticenterpropensitymatchedstudy